# A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Source: https://onco.cc/trials/nct06042894/  
OnCo record `nct06042894` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BL-B01D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer is a phase 2 interventional study registered as NCT06042894 by Sichuan Baili Pharmaceutical Co., Ltd., with 58 participants planned, started 2023-12-12 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1 and SI-B003.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06042894
- Phase: 2
- Setting: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of SI-B003 Monotherapy or BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT06042894: https://clinicaltrials.gov/study/NCT06042894

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06042894.json